The DOI matches its Crossref record; 103 of the 108 references it cites were found in a registry or an index.
ALS Clinical Trials Review: 20 Years of Failure. Are We Any Closer to Registering a New Treatment?
Open accessAbstract
Amyotrophic lateral sclerosis (ALS) is a devastating condition with an estimated mortality of 30,000 patients a year worldwide. The median reported survival time since onset ranges from 24 to 48 months. Riluzole is the only currently approved mildly efficacious treatment. Riluzole received marketing authorization in 1995 in the USA and in 1996 in Europe. In the years that followed, over 60 molecules have been investigated as a possible treatment for ALS. Despite significant research efforts, the overwhelming majority of human clinical trials (CTs) have failed to demonstrate clinical efficacy. In the past year, oral masitinib and intravenous edaravone have emerged as promising new therapeutics with claimed efficacy in CTs in ALS patients. Given their advanced phase of clinical development one may consider these drugs as the most likely near-term additions to the therapeutic arsenal available for patients with ALS. In terms of patient inclusion, CT with masitinib recruited a wider, more representative, less restrictive patient population in comparison to the only successful edaravone CT (edaravone eligibility criteria represents only 18% of masitinib study patients). The present manuscript reviews >50 CTs conducted in the last 20 years since riluzole was first approved. A special emphasis is put on the analysis of existing evidence in support of the clinical efficacy of edaravone and masitinib and the possible implications of an eventual marketing authorisation in the treatment of ALS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Multiple small molecules with anti-inflammatory activity, including minocycline, masitinib, NP001, and celecoxib, have been tested for the treatment of ALS. Although most have failed, masitinib was found to be effective in the preceding clinical trials, and a Phase III clinical trial testing masitinib in ALS patients is ongoing.577”
From Role of neuroinflammation in neurodegeneration development (2023) · cites this paper as [577]
Experimental — accuracy not yet measuredIn the citing paper
“Probiotics are considered to be dietary factors that can influence the human intestinal microbiota, which can affect the composition and structure of the intestinal flora; which, in turn, plays a role in protecting the intestinal epithelial barrier, inhibiting pathogen production, and regulating the immune system (3).”
From Modulation of the gut–brain axis via the gut microbiota: a new era in treatment of amyotrophic lateral sclerosis (2023) · cites this paper as [3]
In the citing paper
“Through use of probiotics, the number of SCFA-producing microorganisms in the intestine can be increased (3).”
From Modulation of the gut–brain axis via the gut microbiota: a new era in treatment of amyotrophic lateral sclerosis (2023) · cites this paper as [3]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Motor Neuron Degeneration in Mice that Express a Human Cu,Zn Superoxide Dismutase Mutation
Gurney, M. E., Pu, H., Chiu, A. Y., Dal Canto, M. C., Polchow, C. Y., Alexander, D. D., Caliendo, J., Hentati, A., Kwon, Y. W., Deng, H.-X., et al. (1994) · Science · doi:10.1126/science.8209258 · Cited by 4,143
Kiernan, M. C., Vucic, S., Cheah, B. C., Turner, M. R., Eisen, A., Hardiman, O., Burrell, J. R., & Zoing, M. C. (2011) · The Lancet · doi:10.1016/s0140-6736(10)61156-7 · Cited by 2,603
A Controlled Trial of Riluzole in Amyotrophic Lateral Sclerosis
Bensimon, G., Lacomblez, L., & Meininger, V. (1994) · New England Journal of Medicine · doi:10.1056/nejm199403033300901 · Cited by 2,239
β-Lactam antibiotics offer neuroprotection by increasing glutamate transporter expression
Rothstein, J. D., Patel, S., Regan, M. R., Haenggeli, C., Huang, Y. H., Bergles, D. E., Jin, L., Dykes Hoberg, M., Vidensky, S., Chung, D. S., et al. (2005) · Nature · doi:10.1038/nature03180 · Cited by 1,518
Dose-ranging study of riluzole in amyotrophic lateral sclerosis
Amyotrophic Lateral Sclerosis/Riluzole Study Group II, Lacomblez, L., Bensimon, G., Meininger, V., Leigh, P. N., & Guillet, P. (1996) · The Lancet · doi:10.1016/s0140-6736(96)91680-3 · Cited by 1,303
Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND)
Miller, R. G., Mitchell, J. D., & Moore, D. H. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001447.pub3 · Cited by 1,123
Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND)
Miller, R. G., Jd, M., Lyon, M., & Moore, D. (2002) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001447 · Cited by 910
Oxidative Stress in Neurodegenerative Diseases
Niedzielska, E., Smaga, I., Gawlik, M., Moniczewski, A., Stankowicz, P., Pera, J., & Filip, M. (2016) · Molecular Neurobiology · doi:10.1007/s12035-015-9337-5 · Cited by 800
Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis
Klivenyi, P., Ferrante, R. J., Matthews, R. T., Bogdanov, M. B., Klein, A. M., Andreassen, O. A., Mueller, G., Wermer, M., Kaddurah-Daouk, R., & Beal, M. F. (1999) · Nature Medicine · doi:10.1038/6568 · Cited by 682
Preclinical research: Make mouse studies work
Perrin, S. (2014) · Nature · doi:10.1038/507423a · Cited by 668
Research works printed but not linked: 5
- ARISLA (Fondazione Italiana de Ricerca Per La Sclerosi Laterale), 2014, ALS Clinical Trials List.
- Bradley, 1995, A phase I/II study of recombinant brain-derived neurotrophic in patients with ALS., Ann. Neurol., 38
- Rosenfeld, 2001, “Creatine monohydrate in amyotrophic lateral sclerosis: preliminary results,” in Proceedings of the, American Academy of Neurology Annual Meeting
- Teva, 2010, News Release.
- Tohgi, 1999, Remarkable increase in cerebrospinal fluid 3-nitrotyrosine in patients with sporadic amyotrophic lateral sclerosis., Ann. Neurol., 46, 129, 10.1002/1531-8249(199907)46:1129::AID-ANA213.0.CO;2-Y · DOI
Cited by
Sorted by citations
Items 201–300 of 451
Delivering Bad News in Amyotrophic Lateral Sclerosis
Edwards, W. F., Malik, S., Peters, J., Chippendale, I., & Ravits, J. (2020) · Neurology Clinical Practice · doi:10.1212/cpj.0000000000000957 · Cited by 16
Castelli, L. M., Lin, Y.-H., Sánchez-Martínez, Á., Gül, A., Imran, K. M., Higginbottom, A., Upadhyay, S. K., Márkus, N. M., Martins, R. R., Cooper‐Knock, J., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.abo3823 · Cited by 16
Tang, J., Kang, Y., Zhou, Y., Chen, Q., Lan, J., Liu, X., & Peng, Y. (2023) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2023.110760 · Cited by 16
Lee, S. Y., Cho, H.-Y., Oh, J.-P., Park, J., Bae, S.-H., Park, H., Kim, E. J., & Lee, J. (2023) · Neurotherapeutics · doi:10.1007/s13311-023-01444-7 · Cited by 21
Endogenous Ligands of TLR4 in Microglia: Potential Targets for Related Neurological Diseases
Chen, B., & Di, B. (2024) · Current Drug Targets · doi:10.2174/0113894501316051240821060249 · Cited by 16
Tang, J., Kang, Y., Zhou, Y., Li, X., Lan, J., Wu, L., Feng, X., & Peng, Y. (2021) · Neurobiology of Disease · doi:10.1016/j.nbd.2021.105315 · Cited by 16
Xie, Y., Luo, X., He, H., & Tang, M. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.657465 · Cited by 16
Exploring the alternative: Fish, flies and worms as preclinical models for ALS
Braems, E., Tziortzouda, P., & Bosch, L. V. D. (2021) · Neuroscience Letters · doi:10.1016/j.neulet.2021.136041 · Cited by 20
Stem Cell Models and Gene Targeting for Human Motor Neuron Diseases
Karpe, Y., Chen, Z.-Y., & Li, X.-J. (2021) · Pharmaceuticals · doi:10.3390/ph14060565 · Cited by 17
Li, C., Zhu, Y., Chen, W., Li, M.-H., Yang, M., Shen, Z., Zhou, Y., Wang, L., Wang, H., Li, S., et al. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.831273 · Cited by 17
Bouscary, A., Quessada, C., René, F., Spedding, M., Henriques, A., Ngo, S. T., & Loeffler, J. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173446 · Cited by 16
Tuddenham, J. F., Fujita, M., Lee, E., Nimmagadda, N., Khairallah, A., Harbison, C., Flowers, X. E., Coronas‐Samano, G., Maniatis, S., Daly, A. C., et al. (2025) · Acta Neuropathologica · doi:10.1007/s00401-025-02913-3 · Cited by 16
Clinical characterization of common pathogenic variants of SOD1-ALS in Germany
Wiesenfarth, M., Forouhideh, Y., Elmas, Z. G., Parlak, Ö., Weiland, U., Herrmann, C. H., Schuster, J., Freischmidt, A., Müller, K., Siebert, R., et al. (2024) · Journal of Neurology · doi:10.1007/s00415-024-12564-1 · Cited by 15
Tang, L., Dorst, J., Chen, L., Liu, X., Ma, Y., Günther, K., Michels, S., Müller, K., Freischmidt, A., Weishaupt, J. H., et al. (2021) · Translational Neurodegeneration · doi:10.1186/s40035-021-00266-x · Cited by 15
The landscape of extracellular vesicles combined with intranasal delivery towards brain diseases
Li, J., Zhang, H., Jiang, Y., Li, N., Zhu, A., Zhang, Y., Feng, K., Zeng, W., Di, L., & Wang, R. (2024) · Nano Today · doi:10.1016/j.nantod.2024.102169 · Cited by 15
Lu, J., He, A.-X., Jin, Z.-Y., Zhang, M., Li, Z., Zhou, F., Ma, L., Jin, H.-M., Wang, J., & Shen, X. (2024) · Acta Pharmacologica Sinica · doi:10.1038/s41401-023-01223-2 · Cited by 14
Yu, M., Xu, J., Dutta, R., Trapp, B. D., Pieper, A. A., & Cheng, F. (2024) · npj Systems Biology and Applications · doi:10.1038/s41540-024-00449-y · Cited by 16
Extracellular vesicles and their diagnostic potential in amyotrophic lateral sclerosis
Roy, J. W., Saucier, D., O’Connell, C. M., & Morin, P. (2019) · Clinica Chimica Acta · doi:10.1016/j.cca.2019.07.012 · Cited by 15
Westerhaus, A., Joseph, T., Meyers, A. J., Jang, Y., Na, C. H., Cave, C., & Sockanathan, S. (2022) · Acta Neuropathologica Communications · doi:10.1186/s40478-022-01376-x · Cited by 14
Liu, L., Wang, N., Lu, Y., & Wang, W.-P. (2018) · Brain and Behavior · doi:10.1002/brb3.1156 · Cited by 14
Fenili, G., Scaricamazza, S., Ferri, A., Valle, C., & Paronetto, M. P. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1421566 · Cited by 13
Lara, A., Esperante, I., Meyer, M., Lière, P., Giorgio, N. P. D., Schumacher, M., Guennoun, R., Gargiulo-Monachelli, G. M., Nicola, A. F. D., & Deniselle, M. C. G. (2021) · Molecular Neurobiology · doi:10.1007/s12035-020-02209-5 · Cited by 13
Mehta, P., Raymond, J. S., Han, M. K., Larson, T. C., III, Berry, J. D., Paganoni, S., Mitsumoto, H., Bedlack, R., & Horton, D. K. (2021) · Journal of Medical Internet Research · doi:10.2196/28021 · Cited by 13
Cai, M., & Yang, E. J. (2022) · Antioxidants · doi:10.3390/antiox11030579 · Cited by 13
Gao, L., Giannousis, P. P., Thoolen, M., Kaushik, D., Latham, J. C., Tansy, A. P., Ma, J., Johnston, M., Dali, M. V., Golden, L., et al. (2022) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.1203 · Cited by 13
A Possible Role for Platelet-Activating Factor Receptor in Amyotrophic Lateral Sclerosis Treatment
Briones, M. R. S., Snyder, A. M., Ferreira, R. C., Neely, E. B., Connor, J. R., & Broach, J. R. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00039 · Cited by 13
Hereditary Motor Neuropathies and Amyotrophic Lateral Sclerosis: a Molecular and Clinical Update
García-Santibáñez, R., Burford, M. J., & Bucelli, R. C. (2018) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-018-0901-z · Cited by 14
Barć, K., Szacka, K., Nieporęcki, K., de Carvalho, M. A., Gromicho, M., Großkreutz, J., Petri, S., Rödiger, A., Steinbach, R., Uysal, H., et al. (2020) · Aging and Disease · doi:10.14336/ad.2019.1120 · Cited by 13
Ohashi, N., Terashima, T., Katagi, M., Nakae, Y., Okano, J., Suzuki, Y., & Kojima, H. (2021) · Scientific Reports · doi:10.1038/s41598-021-92285-x · Cited by 13
Thippakorn, C., Isarankura‐Na‐Ayudhya, C., Pannengpetch, S., Isarankura-Na-Ayudhya, P., Schaduangrat, N., Nantasenamat, C., & Prachayasittikul, V. (2018) · EXCLI journal · doi:10.17179/excli2018-1238 · Cited by 13
Humans: the ultimate animal models
Reilly, M. M., & Rossor, A. M. (2020) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2020-323016 · Cited by 13
Emerging clinical investigational drugs for the treatment of amyotrophic lateral sclerosis
Martínez‐González, L., & Martı́nez, A. (2023) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2023.2178416 · Cited by 12
Neuronal Circuit Dysfunction in Amyotrophic Lateral Sclerosis
Salzinger, A., Ramesh, V., Sharma, S. D., Chandran, S., & Selvaraj, B. T. (2024) · Cells · doi:10.3390/cells13100792 · Cited by 14
Stella, R., Bonadio, R. S., Cagnin, S., Massimino, M. L., Bertoli, A., & Peggion, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22137028 · Cited by 12
Palumbo, M. L., Moroni, A. D., Quiroga, S., Castro, M. M., Burgueño, A. L., & Genaro, A. M. (2021) · Pharmacology Research & Perspectives · doi:10.1002/prp2.795 · Cited by 12
Lamas, N. J., & Roybon, L. (2021) · Frontiers in Drug Discovery · doi:10.3389/fddsv.2021.773424 · Cited by 12
A phase 2, double-blind, placebo-controlled trial of a valproate/lithium combination in ALS patients
Boll, M., Alcaraz-Zubeldia, M., Rı́os, C., González‐Esquivel, D. F., & Montes, S. (2022) · Neurología (English Edition) · doi:10.1016/j.nrleng.2022.07.003 · Cited by 12
Steinbach, R., Prell, T., Gaur, N., Stubendorff, B., Roediger, A., Ilse, B., Witte, O. W., & Großkreutz, J. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9092873 · Cited by 12
Wasted Money in United States Biomedical and Agricultural Animal Research
Keen, J. (2019) · Animal Experimentation: Working Towards a Paradigm Change · doi:10.1163/9789004391192_011 · Cited by 11
Phenotyping Neurodegeneration in Human iPSCs
Li, J., & Fraenkel, E. (2021) · Annual Review of Biomedical Data Science · doi:10.1146/annurev-biodatasci-092820-025214 · Cited by 11
Recapitulating the Angiogenic Switch in a Hydrogel-Based 3D In Vitro Tumor-Stroma Model
Kühlbach, C., Hensler, S., & Mueller, M. M. (2021) · Bioengineering · doi:10.3390/bioengineering8110186 · Cited by 11
Amyotrophic Lateral Sclerosis Risk Genes and Suppressor
Ponnusamy, K., Haider, S., Kumar, R., Malik, M. Z., Singh, M., Rachana, R., & Mani, S. (2022) · Current Gene Therapy · doi:10.2174/1566523223666221108113330 · Cited by 11
Amyotrophic lateral sclerosis: exploring pathophysiology in the context of treatment
Genge, A. L., Wainwright, S., & Velde, C. V. (2023) · Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration · doi:10.1080/21678421.2023.2278503 · Cited by 13
Temporospatial Analysis and New Players in the Immunology of Amyotrophic Lateral Sclerosis
Iyer, A. K., Jones, K. J., Sanders, V. M., & Walker, C. L. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19020631 · Cited by 11
Giusto, E., Codrich, M., de Leo, G., Francardo, V., Coradazzi, M., Parenti, R., Gulisano, M., Vicario, N., Gulino, R., & Leanza, G. (2019) · The Journal of Comparative Neurology · doi:10.1002/cne.24751 · Cited by 11
Stephenson, D. T., Ollivier, C., Brinton, R. D., & Barrett, J. S. (2022) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2528 · Cited by 11
Fasciculation electromechanical latency is prolonged in amyotrophic lateral sclerosis
Planinc, D., Muhamood, N., Cabassi, C., Iniesta, R., Shaw, C., Hodson-Tole, E. F., & Bashford, J. A. (2022) · Clinical Neurophysiology · doi:10.1016/j.clinph.2022.11.005 · Cited by 10
Chronic Intermittent Mild Whole-Body Hypothermia Is Therapeutic in a Mouse Model of ALS
Martin, L. J., Niedzwiecki, M. V., & Wong, M. (2021) · Cells · doi:10.3390/cells10020320 · Cited by 10
Gorrie, G., Chandran, S., Colville, S., Newton, J. L., Leighton, D., McDonald, M., Pal, S., Forbes, R. B., Hair, M. D., & Swingler, R. J. (2019) · Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration · doi:10.1080/21678421.2019.1570271 · Cited by 10
The critical role of persistent sodium current in hippocampal gamma oscillations
Kang, Y., Clement, E. M., Sumsky, S. L., Xiang, Y., Park, I., Santaniello, S., Greenfield, L. J., García‐Rill, E., Smith, B. N., & Lee, S.-H. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.107787 · Cited by 11
Kyllo, T., Allocco, D., Hei, L. V., Wulff, H., & Erickson, J. D. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1466953 · Cited by 9
Nerve Growth Factor is a Potential Treated Target in Tg(SOD1*G93A)1Gur Mice
Xu, Z., Jiang, J., Xu, S., Xie, Z., He, P., Jiang, S., & Xu, R. (2020) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-020-00993-1 · Cited by 9
The preferences of people with amyotrophic lateral sclerosis on riluzole treatment in Europe
Ludolph, A. C., Grandjean, H., Reviers, E., Micheli, V. D., Bianchi, C., Cardosi, L., Russ, H., & Silani, V. (2023) · Scientific Reports · doi:10.1038/s41598-023-49424-3 · Cited by 9
The Scientific and Therapeutic Rationale for Off‐Label Treatments in Amyotrophic Lateral Sclerosis
Bedlack, R., Li, X., Evangelista, B., Panzetta, M. E., Kwan, J. Y., Gittings, L. M., & Sattler, R. (2024) · Annals of Neurology · doi:10.1002/ana.27126 · Cited by 9
Protein production is an early biomarker for RNA ‐targeted therapies
Self, W. K., Schoch, K. M., Alex, J., Barthélemy, N. R., Bollinger, J. G., Sato, C., Cole, T. A., Kordasiewicz, H. B., Swayze, E. E., Bateman, R. J., et al. (2018) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.657 · Cited by 9
Tian, Y., Jin, S., Promes, V., Liu, X., & Zhang, Y. (2020) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-020-02022-w · Cited by 9
Evidence-Based Research Strategy of Traditional Chinese Medicine for Amyotrophic Lateral Sclerosis
Pan, H., Wang, H., Tao, Y., Yuan, J., Xu, S., Ni, J.-L., Huang, M., Wu, X., & Liu, T. (2021) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2021/3402753 · Cited by 9
Mueller, M., Thompson, R., Osman, K. L., Andel, E., DeJonge, C. A., Kington, S., Stephenson, Z., Hamad, A., Bunyak, F., Nichols, N. L., et al. (2022) · Dysphagia · doi:10.1007/s00455-022-10442-4 · Cited by 9
Identifying the molecular drivers of ALS-implicated missense mutations
Portelli, S., Albanaz, A. T. S., Pires, D. E. V., & Ascher, D. B. (2022) · Journal of Medical Genetics · doi:10.1136/jmg-2022-108798 · Cited by 9
Choi, B. J., Park, K. H., Park, M. H., Huang, E. J., Kim, S. H., Bae, J., & Jin, H. K. (2022) · BMB Reports · doi:10.5483/bmbrep.2022.55.12.142 · Cited by 9
Toxicity in ALS: TDP-43 modifiers and C9orf72
Martin, J. L. S., Wang, L., & Kaprielian, Z. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2019.134621 · Cited by 10
Ting, H.-C., Guo, Y., Su, H.-L., Chen, Y.-S., Lin, S., Harn, H., & Chang, C.-Y. (2025) · Cell Death Discovery · doi:10.1038/s41420-025-02302-5 · Cited by 8
Saucier, D., Bélanger, M. F., Liu, Z., Lavigne, É., & O’Connell, C. M. (2025) · Environmental Research · doi:10.1016/j.envres.2025.122232 · Cited by 8
Jankowiak, T., Cholewiński, M., & Bączyk, M. (2022) · Neuroscience · doi:10.1016/j.neuroscience.2022.06.035 · Cited by 9
5-Hydroxytryptamine: a potential therapeutic target in amyotrophic lateral sclerosis
Jiang, S.-S., Gong, M.-N., Rao, W., Chai, W., Chen, W., Zhang, X., Nie, H., & Xu, R. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.367929 · Cited by 8
Kitaoka, Y., Seki, S., Kawata, S., Nishiura, A., Kawamura, K., Hiraoka, S.-I., Kogo, M., & Tanaka, S. (2023) · Nutrients · doi:10.3390/nu15071651 · Cited by 8
Big versus small: The impact of aggregate size in disease
Hnath, B., Chen, J., Reynolds, J., Choi, E. S., Wang, J., Zhang, D., Sha, C. M., & Dokholyan, N. V. (2023) · Protein Science · doi:10.1002/pro.4686 · Cited by 8
Tang, B. L. (2018) · Cells · doi:10.3390/cells7050038 · Cited by 9
Martinez‐Thompson, J. M., & Staff, N. P. (2019) · Oxford University Press eBooks · doi:10.1093/med/9780190862923.003.0095 · Cited by 8
Watts, M. E., Giadone, R. M., Ordureau, A., Holton, K. M., Harper, J. W., & Rubin, L. L. (2024) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2023.1327361 · Cited by 7
Li, L. Y., Park, E., He, C., Abbasi, A. Z., Zhi, P., Fraser, P. E., Rauth, A. M., Henderson, J. T., & Wu, X. Y. (2025) · Advanced Healthcare Materials · doi:10.1002/adhm.202501648 · Cited by 7
Preservation of masseter muscle until the end stage in the SOD1G93A mouse model for ALS
Kawata, S., Seki, S., Nishiura, A., Kitaoka, Y., Iwamori, K., Fukada, S., Kogo, M., & Tanaka, S. (2024) · Scientific Reports · doi:10.1038/s41598-024-74669-x · Cited by 7
Manipulating cell fate while confronting reproducibility concerns
Osterloh, J. M., & Mullane, K. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.01.016 · Cited by 7
Kumar, R., Malik, M. Z., Thanaraj, T. A., Bagabir, S. A., Haque, S., Tambuwala, M. M., & Haider, S. (2023) · Cellular Signalling · doi:10.1016/j.cellsig.2023.110915 · Cited by 7
Analysis of riluzole’s profile of use in a Central Hospital in Lisbon
Paróla, A., Falcão, F., Farinha, H., Caetano, A., Santos, L. G., Medeiros, E., & Baptista, M. V. (2018) · Patient Preference and Adherence · doi:10.2147/ppa.s167861 · Cited by 7
Ustyantseva, E., Medvedev, S. P., Vetchinova, A. S., Illarioshkin, S. N., Leonov, S. V., & Zakian, S. M. (2019) · Stem Cell Research · doi:10.1016/j.scr.2019.101675 · Cited by 7
Chen, X., Sanchez, G. N., Schnitzer, M. J., & Delp, S. L. (2020) · Scientific Reports · doi:10.1038/s41598-019-56555-z · Cited by 7
Intellectual Property Policy at The Neuro, an Open Science InstitutePreprint
Roskams-Edris, D. (2020) · doi:10.32388/omuwel · Cited by 7
Balancing sensitivity and specificity in preclinical researchPreprint
Danziger, M., Collazo, A., Dirnagl, U., & Toelch, U. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.01.17.476585 · Cited by 7
AAV-mediated BDNF and GAS6 muscle delivery delays disease onset in SOD1G93A ALS mice
Le, Y., Liu, G., Wu, S., Nissenbaum, M., Kusnecov, A. W., Furmanski, P., Birge, R. B., & Zhou, R. (2025) · Gene Therapy · doi:10.1038/s41434-025-00577-y · Cited by 6
The neuroprotective role of riluzole in spinal cord injury: a systematic review and meta-analysis
Zarei, H., Khatami, S., Faghihi, M., Bagheri, K. H., Khatami, H., Ghorbanibaroogh, H., Toloui, A., Ramawad, H. A., & Yousefifard, M. (2025) · European Journal of Trauma and Emergency Surgery · doi:10.1007/s00068-025-02907-6 · Cited by 6
Preliminary evidence of links between ayahuasca use and the corpus callosum
Simonsson, O., Bouso, J. C., Kurth, F., de Araújo, D. B., Gaser, C., Riba, J., & Eileen Luders, A. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.1002455 · Cited by 6
Hedges, E. C., Cocks, G. D., Shaw, C. E., & Nishimura, A. L. (2023) · Genes · doi:10.3390/genes14051108 · Cited by 6
A Mini Review on Recent Advancements in the Therapeutic Potentials of Benzothiazoles
Bhutani, R., Kapoor, G., Pathak, D. P., Husain, A., Kant, R., & Ali, R. (2019) · Current Bioactive Compounds · doi:10.2174/1573407216666191223093550 · Cited by 6
In vitro modelling of human proprioceptive sensory neurons in the neuromuscular system
Badiola-Mateos, M., Osaki, T., Kamm, R. D., & Samitier, J. (2022) · Scientific Reports · doi:10.1038/s41598-022-23565-3 · Cited by 6
Immunization with Neural-Derived Peptides in Neurodegenerative Diseases: A Narrative Review
Monroy, G. R., Pérez, R. M., Ben-Zión, E. W., Alcantar-Garibay, O., Loza-López, E. C., Marion, E. T., Blancarte-Hernández, E., Navarro-Torres, L. K., & Ibarra, A. (2023) · Biomedicines · doi:10.3390/biomedicines11030919 · Cited by 6
Short structural variants as informative genetic markers for ALS disease risk and progression
Theunissen, F., Flynn, L. L., Anderton, R. S., & Akkari, P. A. (2022) · BMC Medicine · doi:10.1186/s12916-021-02206-y · Cited by 6
Ageing, Neurodegeneration and the Endocannabinoid System
Fernández‐Ruíz, J., Sagredo, O., Gómez‐Ruíz, M., & de Lago, E. (2025) · Current topics in behavioral neurosciences · doi:10.1007/7854_2025_597 · Cited by 5
Epplen, A. S. C., Rothöft, M., Stahlke, S., Theiß, C., & Matschke, V. (2025) · Cell Communication and Signaling · doi:10.1186/s12964-025-02415-5 · Cited by 5
The Effect of Skeletal Muscle-Specific Creatine Treatment on ALS NMJ Integrity and Function
Badu-Mensah, A., Guo, X., Mendez, R., Parsaud, H., & Hickman, J. J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241713519 · Cited by 5
Wang, Y., Liang, W., Wang, T., Zhang, C., Yang, Y., Cong, C., Wang, X., Wang, S., Wang, D., Huo, D., et al. (2023) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2023.110792 · Cited by 5
Eckardt, A., Marble, C., Fern, B., Moritz, H., Kotula, C. A., Ke, J., Rebancos, C., Robertson, S., Nishimune, H., & Suzuki, M. (2025) · Frontiers in Neuroscience · doi:10.3389/fnins.2025.1527181 · Cited by 5
Luo, X., Gutierrez, H. V., Rutkove, S. B., & Sanchez, B. (2021) · IEEE Open Journal of Engineering in Medicine and Biology · doi:10.1109/ojemb.2021.3117871 · Cited by 5
Alaskarov, A., Barel, S., Bakavayev, S., Kahn, J., & Israelson, A. (2022) · Scientific Reports · doi:10.1038/s41598-022-13744-7 · Cited by 5
Optineurin Dysfunction in Amyotrophic Lateral Sclerosis: Why So Puzzling?
Prtenjača, N. (2020) · Periodicum Biologorum · doi:10.18054/pb.v121-122i1-2.10627 · Cited by 5
Glavač, D., Mladinić, M., Ban, J., Mazzone, G. L., Sámano, C., Tomljanović, I., Jezernik, G., & Ravnik‐Glavač, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911360 · Cited by 5
Kondo, T., Inoue, I., Umeyama, K., Watanabe, M., Matsunari, H., Uchikura, A., Nakano, K., Tsukita, K., Imamura, K., Nagashima, H., et al. (2023) · Laboratory Investigation · doi:10.1016/j.labinv.2022.100013 · Cited by 4
A phase 2, double-blind, placebo-controlled trial of a valproate/lithium combination in ALS patients
Boll, M., Alcaraz-Zubeldia, M., Rı́os, C., González‐Esquivel, D. F., & Montes, S. (2025) · Neurología · doi:10.1016/j.nrl.2022.07.003 · Cited by 4
Drug Combination to Slow Down the Progression of Amyotrophic Lateral Sclerosis
Torres-Rico, M., Marín-Rodríguez, B., Arasmou-Idrovo, M. S., Garcı́a, A. G., & Pascual-Guerra, J. (2025) · Current Treatment Options in Neurology · doi:10.1007/s11940-025-00835-9 · Cited by 4
Karimi, S., Ghaheri, A., Madani, H., Maal, A. B., Sadri, B., Khodadoust, E., Sharafi, F., Vosough, M., & Nabavi, S. M. (2025) · Neurodegenerative Disease Management · doi:10.1080/17582024.2025.2553499 · Cited by 4
Metadata
- Authors
- Petrov, D., Mansfield, C., Moussy, A., & Hermine, O.
- Affiliations
- AB Science (France) (FR)
- Hôpital Necker-Enfants Malades (FR)
- Corresponding author
- Hermine, Olivier
- Venue
- Frontiers in Aging Neuroscience
- Publisher
- Frontiers Media SA
- Published
- 2017-03-22
- Volume
- 9
- Pages
- 68-68
- ISSN
- 1663-4365 (ISSN-L)
- PMC
- PMC5360725
- OpenAlex
- W2597399186
- Cited by
- 451
- References
- 108
- Citations by year
- 2026: 28 · 2025: 41 · 2024: 45 · 2023: 46 · 2022: 65 · 2021: 63 · 2020: 53 · 2019: 52 · 2018: 50 · 2017: 8
- FWCI
- 5.94
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- Frontiers in Aging Neuroscience (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Agence Nationale de la Recherche (ANR-11-LABX-0051)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
- Keywords
- amyotrophic lateral sclerosis, clinical trial failure, riluzole, edaravone, masitinib, drug development, clinical efficacy, patient selection criteria, drug approval, neurodegenerative disease therapeutics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
